Mankind Pharma Limited Stock

Equities

MANKIND

INE634S01028

Pharmaceuticals

Market Closed - NSE India S.E. 07:42:31 2024-04-30 am EDT 5-day change 1st Jan Change
2,364 INR -0.53% Intraday chart for Mankind Pharma Limited +1.03% +19.26%
Sales 2024 * 103B 1.24B Sales 2025 * 117B 1.4B Capitalization 947B 11.34B
Net income 2024 * 18.3B 219M Net income 2025 * 21.75B 261M EV / Sales 2024 * 8.94 x
Net cash position 2024 * 25.25B 302M Net cash position 2025 * 43.42B 520M EV / Sales 2025 * 7.75 x
P/E ratio 2024 *
51.7 x
P/E ratio 2025 *
43.4 x
Employees 18,468
Yield 2024 *
0.29%
Yield 2025 *
0.41%
Free-Float 19.91%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.53%
1 week+1.03%
Current month+2.77%
1 month+2.77%
3 months+13.05%
6 months+34.43%
Current year+19.26%
More quotes
1 week
2 355.05
Extreme 2355.05
2 452.45
1 month
2 241.10
Extreme 2241.1
2 490.00
Current year
1 980.00
Extreme 1980
2 490.00
1 year
1 242.00
Extreme 1242
2 490.00
3 years
1 242.00
Extreme 1242
2 490.00
5 years
1 242.00
Extreme 1242
2 490.00
10 years
1 242.00
Extreme 1242
2 490.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 48 07-09-20
Director of Finance/CFO 55 16-06-16
Compliance Officer - 16-09-22
Members of the board TitleAgeSince
Director/Board Member 60 22-07-31
Director/Board Member 71 22-07-31
Director/Board Member 61 15-02-18
More insiders
Date Price Change Volume
24-04-30 2,364 -0.53% 231,691
24-04-29 2,377 +0.34% 209,100
24-04-26 2,369 -1.23% 197,510
24-04-25 2,399 +0.01% 186,814
24-04-24 2,398 +0.22% 569,613

Delayed Quote NSE India S.E., April 30, 2024 at 07:42 am EDT

More quotes
Mankind Pharma Limited is an India-based pharmaceutical company. The Company is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It has a portfolio of formulations in several therapeutic areas, such as anti-infectives, cardiovascular, gastrointestinal, vitamins/minerals/nutrients, respiratory, anti-diabetic, dermatology, gynecology, and pain/analgesics, among others. Its other therapeutic areas include urology, ophthalmology, antiparasitic, stomatological, antineoplastic/immunomodulator, hepatoprotective, anti-malarial, blood-related, hormones, antiviral, sex stimulants/rejuvenators, anti-tuberculosis, parenteral and vaccines. Its portfolio of brands includes Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, Dynaglipt, and others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
2,364 INR
Average target price
2,186 INR
Spread / Average Target
-7.53%
Consensus
  1. Stock Market
  2. Equities
  3. MANKIND Stock